Cell-free microRNA-148a is associated with renal allograft dysfunction: Implication for biomarker discovery

Area of Science:

• Nephrology
• Epigenetics
• Molecular Biology

Background:

• Chronic allograft dysfunction (CAD) is the primary cause of kidney graft loss.
• Epigenetic biomarkers, particularly microRNAs (miRNAs), show promise in reflecting disease status and treatment response.
• Circulating miRNAs may offer insights into the progression of renal allograft dysfunction.

Purpose of the Study:

• To investigate the potential of circulating miRNA-148a as a predictor of renal graft function.
• To evaluate the association of miRNA-148a levels with histological findings and clinical parameters in kidney transplant recipients.
• To determine if miRNA-148a can differentiate between stable graft function and chronic allograft dysfunction.

Main Methods:

• Plasma samples were collected from kidney transplant recipients with interstitial fibrosis and tubular atrophy (IFTA) and stable graft function (SGF), as well as healthy controls.
• Quantitative polymerase chain reaction (qPCR) was used to measure the levels of circulating miRNA-148a.
• Correlations between miRNA-148a levels and clinical (serum creatinine, glomerular filtration rate) and histological parameters were analyzed.

Main Results:

• MiRNA-148a levels were significantly decreased in patients with IFTA compared to those with SGF.
• Lower miRNA-148a expression correlated with increased serum creatinine and decreased glomerular filtration rate.
• MiRNA-148a demonstrated high diagnostic accuracy in discriminating IFTA from SGF, with an area under the curve of 0.89.

Conclusions:

• Plasma cell-free miRNA-148a levels correlate with renal function and histological damage in kidney transplant recipients.
• MiRNA-148a may serve as a novel, noninvasive molecular marker for monitoring the progression of IFTA.
• This emerging biomarker holds potential as a future therapeutic target for chronic allograft dysfunction.